The Retinopathy drugs in development market research report provides comprehensive information on the therapeutics under development for Retinopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Retinopathy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Retinopathy - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Retinopathy and features dormant and discontinued products.

GlobalData tracks 198 drugs in development for Retinopathy by 163 companies/universities/institutes. The top development phase for Retinopathy is preclinical with 131 drugs in that stage. The Retinopathy pipeline has 185 drugs in development by companies and 13 by universities/ institutes. Some of the companies in the Retinopathy pipeline products market are: ANBITION, Unity Biotechnology and Palatin Technologies.

The key targets in the Retinopathy pipeline products market include Vascular Endothelial Growth Factor A (Vascular Permeability Factor or VEGFA), Vascular Endothelial Growth Factor (VEGF) , and Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF).

The key mechanisms of action in the Retinopathy pipeline product include Vascular Endothelial Growth Factor A (Vascular Permeability Factor or VEGFA) Inhibitor with 14 drugs in Phase III. The Retinopathy pipeline products include 15 routes of administration with the top ROA being Intravitreal and 16 key molecule types in the Retinopathy pipeline products market including Small Molecule, and Monoclonal Antibody.

Retinopathy overview

Retinopathy is any damage to the retina of the eyes, which may cause vision impairment. Retinopathy often refers to retinal vascular disease, or damage to the retina caused by abnormal blood flow. Retinopathy, or retinal vascular disease, can be broadly categorized into proliferative and non-proliferative types. Frequently, retinopathy is an ocular manifestation of a systemic disease such as diabetes or hypertension.

For a complete picture of Retinopathy’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.